J. Orme

发表

Macrophage subpopulations in systemic lupus erythematosus.

C. Mohan, J. Orme, 2012, Discovery medicine.

Macrophages and neutrophils in SLE-An online molecular catalog.

C. Mohan, J. Orme, 2012, Autoimmunity reviews.

Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression

Yundong He, Wanhai Xu, Yunqian Pan, 2021, Cancer Research.

Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.

L. Davis, J. Hutcheson, Tianfu Wu, 2016, Clinical immunology.

Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer

J. Cheville, I. Frank, B. Costello, 2022, BMC Urology.

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

A. Mansfield, J. Orme, Haidong Dong, 2020, Oncoimmunology.

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Sean S. Park, A. Mansfield, S. Markovic, 2020, Journal for ImmunoTherapy of Cancer.

Rational Second-Generation Antiandrogen Use in Prostate Cancer

Sean S. Park, B. Costello, J. Orme, 2022, The oncologist.

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy

Sean S. Park, N. Foster, J. Orme, 2022, BMJ Open.

Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

Yohan Kim, Mojun Zhu, A. Mansfield, 2022, bioRxiv.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination.

J. Orme, D. Purushotham, 2017, The American journal of medicine.

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study

E. Compérat, J. Orme, G. Schäfer, 2021, Journal of clinical medicine.

Radiotherapy in Oligometastatic Prostate Cancer.

Sean S. Park, B. Costello, B. Stish, 2022, International Journal of Radiation Oncology, Biology, Physics.

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Liewei Wang, M. Gleave, Yuzhuo Wang, 2021, Nature Communications.

An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.

Liguo Wang, Yunqian Pan, Haojie Huang, 2021, Cell reports.

A targetable epigenetic vulnerability in PI3K/AKT inhibitor resistant cancers

Liguo Wang, Yunqian Pan, Haojie Huang, 2020, bioRxiv.

Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience

B. Costello, J. Orme, L. Pagliaro, 2021, The Prostate.

Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity

Sean S. Park, V. Lowe, Yohan Kim, 2022, International journal of radiation oncology, biology, physics.

Circulating Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in 11C Choline-identified Oligometastatic Castration-Refractory Prostate Cancer Treated with Stereotactic Ablative Radiotherapy

V. Lowe, W. Harmsen, J. Orme, 2021, medRxiv.

HUS1 as a Potential Therapeutic Target in Urothelial Cancer

T. Furlan, J. Orme, D. D’andrea, 2022, Journal of clinical medicine.

Leukocyte Beta-Catenin Expression Is Disturbed in Systemic Lupus Erythematosus

Tianfu Wu, C. Mohan, A. Satterthwaite, 2016, PloS one.

Economic Cost and Sustainability of Oral Therapies in Precision Oncology

J. Orme, A. Desai, C. Scheckel, 2022, JCO oncology practice.

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities

J. Cheville, B. Costello, J. Orme, 2023, The oncologist.

Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Sean S. Park, V. Lowe, B. Costello, 2021, Clinical Cancer Research.

Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

N. Shah, A. Adjei, J. Orme, 2022, JAMA Network Open.

Microenvironment-Mediated Resistance to Anti-Androgen Therapy.

Haojie Huang, J. Orme, 2020, Cancer cell.

Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM.

G. Mer, Haojie Huang, J. Orme, 2023, Molecular cell.

Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy

C. Loprinzi, J. Orme, K. Ruddy, 2022, JCO oncology practice.

Heightened Crescentic Glomerulonephritis in Immune Challenged 129sv Mice Is TGF-β/Smad3 Dependent

C. Mohan, J. Orme, C. Xie, 2021, International journal of molecular sciences.

A genopedia of lupus genes - lessons from gene knockouts.

C. Mohan, J. Orme, Yuyuan Guo, 2013, Current rheumatology reviews.

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma

W. Horninger, J. Orme, A. Brunner, 2021, BJU international.

The economic cost and sustainability of the precision oncology promise.

J. Orme, A. Desai, C. Scheckel, 2021, Journal of Clinical Oncology.

Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.

L. Davis, J. Hutcheson, Tianfu Wu, 2016, Clinical immunology.

Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation

J. Orme, F. Lucien, M. Grams, 2023, Science advances.

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

E. Sokol, O. Smaletz, E. Antonarakis, 2023, European urology oncology.

SETDB1 modulates degradation of phosphorylated RB and anti-cancer efficacy of CDK4/6 inhibitors.

Xin Jin, Yunqian Pan, Haojie Huang, 2023, Cancer research.